FIRST GOAL OF THE STUDY1,2
To measure the effectiveness of AUSTEDO on:
- HD chorea symptoms using the Total Maximal
Chorea (TMC) score - TMC score progress before, during, and at the
end of the 12-week study
ABOUT THE CLINICAL STUDY
A clinical study measured the effects of AUSTEDO in people
with Huntington’s disease (HD) chorea1*
SECOND GOAL OF THE STUDY1,2
To evaluate the effects of AUSTEDO on:
- Overall HD symptoms, as reported
by people and their doctors - Limitations on people’s ability to
perform daily activities
About the study1:
90 people with HD chorea were studied for 12 weeks.
45 people were selected to take AUSTEDO (deutetrabenazine) tablets and 45 people were
selected to take placebo (inactive tablets).
Involuntary movements were measured at the beginning and end of the study, with movements
also being observed at intervals throughout the 12-week period.*
*Once-daily AUSTEDO XR contains the same active ingredient as twice-daily AUSTEDO. Data on this page is based on twice-daily dosing.1
Sex2
FEMALE
44.4%
MALE
55.6%
Medications people taking AUSTEDO were able
to continue throughout the trial2
ANTIDEPRESSANTS
62.2%
Antiepileptics
35.5%
Antianxiety
medications
15.5%
The TMC score is used to determine the effectiveness of HD chorea treatment. Seven parts of the body—including the face, mouth, arms, and legs—are scored from 0 to 4, with 0 indicating no chorea. A complete TMC score ranges from 0 to 28. The lower the score, the less chorea, or involuntary movements, exhibited by the person.1,2
If your doctor recommends switching to AUSTEDO XR from tetrabenazine, you can start AUSTEDO XR the day after you stop tetrabenazine. This means you can continue treating your HD chorea without missing a dose.
In a clinical study, 37 people with HD chorea switched overnight from tetrabenazine to AUSTEDO. People in the study received AUSTEDO at approximately half the dose of tetrabenazine.
Last Dose
tetrabenazine
NEXT DAY
First Dose
AUSTEDO XR
Stay in the know
Sign up for HD chorea treatment tips, information
about patient support, and educational resources.
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
References:
1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
3. Frank S, Stamler D, Kayson E, et al; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977‐982.